Medical/Pharmaceuticals
AnPac Bio-Medical Science Enters into Definitive Agreement to Make Another Acquisition to Significantly Expand Scope of Business in the U.S.
NEW YORK, Feb. 13, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations inthe United States andChina announced that on February 12, 2023, the Company, through its subsidiary Foodbase Group Inc., entered into a definitive equity purchas...
2023-02-13 21:00
4626
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
Approval follows U.S. FDA clearance of IND application for BCMA/CD19 dual-targeting FasTCAR-T GC012F Company plans to initiate Phase 1/2 clinical trial in China in third quarter of 2023 SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Feb. 13, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ...
2023-02-13 20:30
3197
B dot Medical to Install Ultra-compact Proton Therapy System at Thammasat University in Thailand
- Responding to Growing Needs for Urban-type Proton Therapy in Thailand - TOKYO and BANGKOK, Feb. 13, 2023 /PRNewswire/ -- B dot Medical Inc. and Thammasat University, a leading national university in Thailand, have signed a memorandum of understanding to install the ultra-compact proton therapy ...
2023-02-13 14:00
3209
Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World's First Topical Use PROTAC Compound
SUZHOU, China, Feb. 10, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced the positive top-line results from the U.S. Phase I clinical trial of GT200...
2023-02-10 21:19
4962
HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities
* HanAll will invest in Interon Laboratories, a preclinical-stage biotechnology company focused on treating complex neurological disorders * Interon is developing a new category of immunotherapy for people with neurological and immune disorders starting with autism spectrum disorder SEOUL, So...
2023-02-10 20:00
3949
Nona Biosciences Enters into HCAb Based Antibody Discovery Collaboration Agreement with Mythic Therapeutics
CAMBRIDGE, Mass., Feb. 10, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to cutting edge technology innovations, and providing a total solution from "Idea to IND" ("I to ITM"), today announced that it has entered into a collaboration agreement ...
2023-02-10 13:00
2979
US based COBRA diagnostic prostate cancer trial reaches recruitment target
SYDNEY, Feb. 9, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce its diagnostic 64Cu SAR-...
2023-02-09 22:03
3253
Hugel Achieved Record-High Revenue and Operating Profit
* Hugel delivered 2022 revenue of KRW281.7bn, operating profit of KRW102.5bn, up 21.5% YoY and 7.2% YoY, respectively * Botulinum toxin's sales soared by 28.9% YoY; European sales in full swing * Hugel aims to obtain marketing approval and launch products in the U.S. within this year SEOUL, ...
2023-02-09 22:00
3819
First Prescription for COSELA® (trilaciclib) Issued in China
- COSELA®, the world's first and only myeloprotection drug, was prescribed in Jilin Cancer Hospital onJanuary 28, 2023 - Simcere delivers drug to patients in 908 days from execution of license agreement to first prescription NANJING, China, Feb. 9, 2023 /PRNewswire/ -- Simcere Pharmaceutical Gr...
2023-02-09 21:00
4216
Technoderma Medicines Initiates TDM-180935 Atopic Dermatitis Clinical Program with Phase 1 Dose Escalation Trial
SAN DIEGO, Feb. 9, 2023 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report the Company has begun dosing healthy volunteer subjects in its Phase 1 clinical trial of topical TDM-180935 ointment. This first clinical trial in ...
2023-02-09 21:00
2293
AnPac Bio-Medical Science Enters into Definitive Agreement to Acquire Fresh2 Ecommerce Inc, a B2B Asian Food E-commerce Platform
Transaction expected to fuel the Company's growth in the U.S. food market NEW YORK, Feb. 9, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations inthe United States andChina focused on early cancer screening and detection and plans to ...
2023-02-09 21:00
4034
GC Biopharma Receives WHO Pre-Qualification for Filling and Finish Plant in Ochang, South Korea
YONGIN, South Korea, Feb. 8, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, announced today that the World Health Organization (WHO) has awarded prequalification to filling and finish plant onFebruary 3 2023, located in Ochang, South...
2023-02-09 09:21
2752
ImmVira Clinical Snapshot: Intratumoral Injected OV (MVR-T3011 IT) Monotherapy Achieved Median PFS of 12.9 Months on Treatment of Melanoma
SHENZHEN, China, Feb. 8, 2023 /PRNewswire/ -- ImmVira's first intratumoral injected OV product MVR-T3011 IT has shown positive efficacy in the course of clinical studies in the U.S. andChina as of January 2023, with which the monotherapy treatment significantly prolonged PFS to a median of 12.9 m...
2023-02-09 08:00
2558
ReviR Therapeutics and Asieris Pharmaceuticals Enter into Agreement to Discover Oncology Therapeutics Based on ReviR's Comprehensive Approach to RNA-targeted Technologies
SAN FRANCISCO, Feb. 8, 2023 /PRNewswire/ -- ReviR Therapeutics, a privately held developer of a suite of small molecule RNA-targeting technologies for cancer and other genetically-defined diseases, and Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing, an...
2023-02-08 22:00
3194
SUMMIT HEALTHCARE ACQUISITION CORP. AND YS BIOPHARMA ANNOUNCE EFFECTIVENESS OF REGISTRATION STATEMENT AND EXTRAORDINARY GENERAL MEETING DATE FOR PROPOSED BUSINESS COMBINATION
* Extraordinary general meeting of Summit Healthcare Acquisition Corp.'s shareholders to be held onMarch 1, 2023 at 9:00 a.m. Eastern Time * YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines a...
2023-02-08 21:30
3885
Lunit and Agfa HealthCare bring breast imaging AI solution to Dubai Academic Health Corporation (DAHC) Dubai Hospital
* Dubai Academic Health Corporation (DAHC) Dubai Hospital to modernize its Breast Cancer Diagnostic and Screening program with Agfa HealthCare's RUBEE for AI framework and Lunit INSIGHT MMG algorithm * The Breast AI Analysis Package is Lunit's first application with Agfa HealthCare since form...
2023-02-08 21:05
3344
Meihua International Medical Technologies Co. Explores Application of ChatGPT Technologies to Develop Online AI Health Consultation Services
YANGZHOU, China, Feb. 8, 2023 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries inChina, today announced the Company will...
2023-02-08 20:30
2400
SK bioscience Announces the Largest Investment Ever to Establish Songdo Global Research & Process Development Center
* The additional investment for the 'R&PD Center' was confirmed by the board of directors committee with a total of261 million USD * SK bioscience plans to establish a vaccine-biopharmaceutical hub, organizing a global cooperative model against new pandemics SEONGNAM, South Korea, Feb. 8, 202...
2023-02-08 20:00
3140
Infectious disease specialist Dr. Regis A. Vilchez is appointed CMO of MicuRx Pharmaceuticals, Inc.
SHANGHAI, Feb. 8, 2023 /PRNewswire/ -- Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx," 688373) announced recently that it has appointedRegis A. Vilchez, MD, PhD, an experienced R&D biopharmaceutical executive and infectious disease expert, as Chief Medical Officer of its American subsidiary, ...
2023-02-08 16:05
3388
Orion Health reinforces security credentials with HITRUST and DirectTrust accreditations
HITRUST Risk-based, 2-year Certification for Amadeus validates commitment to protecting sensitive information, while Communicate product also achieves DirectTrust™ HISP Accreditation AUCKLAND, New Zealand, Feb. 7, 2023 /PRNewswire/ -- Orion Health, a global leader in population health software, ...
2023-02-08 12:40
3321
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 281 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24
Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines
[Picked up by 263 media titles]
2026-10-02 16:27
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
24713